Specifica-Sanofi agreement to enable antibody discovery platform integration

By The Science Advisory Board staff writers

June 13, 2022 -- Specifica and Sanofi have reached an agreement under which Specifica’s Generation 3 Antibody Discovery Platform will be transferred enabling the integration into Sanofi’s antibody discovery programs.

Specifica's Gen 3 discovery platform yields a broad diversity of specific and developable antibodies with very high affinities, thereby avoiding downstream hit-to-lead optimization bottlenecks such as affinity maturation and developability optimization, according to the company.

The Gen 3 libraries combine clinically validated antibody frameworks with compatible binding loop sequences from natural human antibodies that have been purged of sequence-based developability liabilities.

Specifica CEO Ken Sharples in a statement said the partnership with Sanofi will provide a "complete antibody discovery platform through a combination of Gen 3 libraries, antibody optimization solutions, and integrated discovery tools."

Specifica highlights research for its antibody discovery platform
Specifica, a privately held antibody engineering company focused on in vitro antibody library and discovery tools, announced the publication of two peer-reviewed...
Specifica transfers antibody discovery platform to Bayer
Specifica announced the transfer of its Generation 3 antibody libraries to Bayer under an agreement that will enable the company to develop antibody-based...

Copyright © 2022 scienceboard.net

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter